181 related articles for article (PubMed ID: 15069957)
1. Balancing access to pharmaceuticals with patent rights.
Nicol D
Monash Bioeth Rev; 2003 Apr; 22(2):50-62. PubMed ID: 15069957
[TBL] [Abstract][Full Text] [Related]
2. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
3. The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements.
Cohen JC; Illingworth P
Dev World Bioeth; 2003 May; 3(1):27-48. PubMed ID: 14577451
[TBL] [Abstract][Full Text] [Related]
4. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
Resnik DB; DeVille KA
Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
[No Abstract] [Full Text] [Related]
5. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
6. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
Schuklenk U
Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
[No Abstract] [Full Text] [Related]
7. Patent immorality?
Bloche MG; Jungman ER
Am J Bioeth; 2002; 2(3):48-9. PubMed ID: 12230859
[No Abstract] [Full Text] [Related]
8. Pharmaceuticals and medical devices: business practices.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
[No Abstract] [Full Text] [Related]
9. Compulsory licensure: the case of Cipro and beyond.
Chakrabarty AM
Am J Bioeth; 2002; 2(3):40. PubMed ID: 12230853
[No Abstract] [Full Text] [Related]
10. India's pharmaceutical industry: hype or high tech take-off?
Malhotra P; Lofgren H
Aust Health Rev; 2004 Nov; 28(2):182-93. PubMed ID: 15527398
[TBL] [Abstract][Full Text] [Related]
11. [How are prices for important drugs stipulated in poor countries?].
Lien L
Tidsskr Nor Laegeforen; 2003 Apr; 123(7):958-9. PubMed ID: 12737074
[No Abstract] [Full Text] [Related]
12. Patent watch.
Harrison C
Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
[No Abstract] [Full Text] [Related]
13. The Cipro patent and bioterrorism.
Kaye KS; Kaye D
Am J Bioeth; 2002; 2(3):41-2. PubMed ID: 12230854
[No Abstract] [Full Text] [Related]
14. Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere.
Baker BK
PLoS Med; 2016 Mar; 13(3):e1001970. PubMed ID: 26954325
[TBL] [Abstract][Full Text] [Related]
15. Patent watch: the patent cliff steepens.
Harrison C
Nat Rev Drug Discov; 2011 Jan; 10(1):12-3. PubMed ID: 21193859
[No Abstract] [Full Text] [Related]
16. [Patents and availability of essential drugs].
Carné X
Med Clin (Barc); 2007 Nov; 129(16):617-8. PubMed ID: 18001674
[No Abstract] [Full Text] [Related]
17. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
18. The GO License: only part of the solution.
Batson A; Milstien JB
Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
[TBL] [Abstract][Full Text] [Related]
19. Taking TRIPS to India--Novartis, patent law, and access to medicines.
Mueller JM
N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
[No Abstract] [Full Text] [Related]
20. Out-licensing: a practical approach for improvement of access to medicines in poor countries.
Friedman MA; den Besten H; Attaran A
Lancet; 2003 Jan; 361(9354):341-4. PubMed ID: 12559883
[No Abstract] [Full Text] [Related]
[Next] [New Search]
